Drugs / Cell-culture rabies vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02207816 Comparator | Sep 2014 → Jan 2017 | malaria | GlaxoSmithKline | Completed | Missed primary |
| Phase 3 | NCT00866619 Comparator | Mar 2009 → Mar 2011 | malaria | GlaxoSmithKline | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cell-culture rabies vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02207816 ↗ |
| Modality | Vaccine | “comparator (meningococcal or rabies) vaccines” PMID 31708182 ↗ Nov 2019 |
| Route | Intramuscular | “administered intramuscularly into the left deltoid.” NCT00866619 ↗ |